Evolution of Experimental Models of the Liver to Predict Human Drug Hepatotoxicity and Efficacy

Overview

Journal Clin Liver Dis

Specialty Gastroenterology

Date 2016 Nov 16

PMID 27842772

Citations 16

Authors

Lawrence A Vernetti

Andreas Vogt

Albert Gough

D Lansing Taylor

Affiliations

Soon will be listed here.

Abstract

In this article, we review the past applications of in vitro models in identifying human hepatotoxins and then focus on the use of multiscale experimental models in drug development, including the use of zebrafish and human cell-based, 3-dimensional, microfluidic systems of liver functions as key components in applying Quantitative Systems Pharmacology (QSP). We have implemented QSP as a platform to improve the rate of success in the process of drug discovery and development of therapeutics.

Citing Articles

Vitrification and rapid rewarming of precision-cut liver slices for pharmacological and biomedical research.

Ramesh S, Rao J, Namsrai B, Fisher B, Tobolt D, Megaly M bioRxiv. 2024; .

PMID: 39713303 PMC: 11661125. DOI: 10.1101/2024.12.08.627273.

Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.

Xia M, Varmazyad M, Pla-Palacin I, Gavlock D, DeBiasio R, LaRocca G Front Cell Dev Biol. 2024; 12:1423936.

PMID: 39324073 PMC: 11422722. DOI: 10.3389/fcell.2024.1423936.

Microfluidic gut-axis-on-a-chip models for pharmacokinetic-based disease models.

Kim R, Sung J Biomicrofluidics. 2024; 18(3):031507.

PMID: 38947281 PMC: 11210976. DOI: 10.1063/5.0206271.

In Vitro Hepatotoxicity of Routinely Used Opioids and Sedative Drugs.

Haller K, Doss S, Sauer M Curr Issues Mol Biol. 2024; 46(4):3022-3038.

PMID: 38666919 PMC: 11049542. DOI: 10.3390/cimb46040189.

Synthesis, Computational, and Anticancer In Vitro Investigations of Aminobenzylnaphthols Derived from 2-Naphtol, Benzaldehydes, and α-Aminoacids via the Betti Reaction.

Kciuk M, Malinowska M, Gielecinska A, Sundaraj R, Mujwar S, Zawisza A Molecules. 2023; 28(20).

PMID: 37894709 PMC: 10609152. DOI: 10.3390/molecules28207230.

References

Kanebratt K, Andersson T . Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos. 2008; 36(7):1444-52. DOI: 10.1124/dmd.107.020016. View

Cheng A, Dixon S . In silico models for the prediction of dose-dependent human hepatotoxicity. J Comput Aided Mol Des. 2004; 17(12):811-23. DOI: 10.1023/b:jcam.0000021834.50768.c6. View

Lubberstedt M, Muller-Vieira U, Mayer M, Biemel K, Knospel F, Knobeloch D . HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods. 2010; 63(1):59-68. DOI: 10.1016/j.vascn.2010.04.013. View

Prodanov L, Jindal R, Bale S, Hegde M, McCarty W, Golberg I . Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng. 2015; 113(1):241-6. PMC: 4967935. DOI: 10.1002/bit.25700. View

Greene N, Fisk L, Naven R, Note R, Patel M, Pelletier D . Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010; 23(7):1215-22. DOI: 10.1021/tx1000865. View

Senutovitch N, Vernetti L, Boltz R, DeBiasio R, Gough A, Taylor D . Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med (Maywood). 2015; 240(6):795-808. PMC: 4464952. DOI: 10.1177/1535370215584934. View

Stern A, Schurdak M, Bahar I, Berg J, Taylor D . A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. J Biomol Screen. 2016; 21(6):521-34. PMC: 4917453. DOI: 10.1177/1087057116635818. View

Ito K, Houston J . Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res. 2004; 21(5):785-92. DOI: 10.1023/b:pham.0000026429.12114.7d. View

Aleo M, Luo Y, Swiss R, Bonin P, Potter D, Will Y . Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014; 60(3):1015-22. DOI: 10.1002/hep.27206. View

10.

Wang Y, Chai S, Brewer C, Chen T . Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2014; 10(11):1521-32. PMC: 4198438. DOI: 10.1517/17425255.2014.963555. View

11.

Nam K, Smith A, Lone S, Kwon S, Kim D . Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening. J Lab Autom. 2014; 20(3):201-15. PMC: 4459652. DOI: 10.1177/2211068214557813. View

12.

Brandon E, Raap C, Meijerman I, Beijnen J, Schellens J . An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol. 2003; 189(3):233-46. DOI: 10.1016/s0041-008x(03)00128-5. View

13.

Poon K, Wang X, Ng A, Goh W, McGinnis C, Fowler S . Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates. Arch Toxicol. 2016; 91(3):1187-1197. DOI: 10.1007/s00204-016-1789-5. View

14.

Sakatis M, Reese M, Harrell A, Taylor M, Baines I, Chen L . Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem Res Toxicol. 2012; 25(10):2067-82. DOI: 10.1021/tx300075j. View

15.

Usui T, Mise M, Hashizume T, Yabuki M, Komuro S . Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos. 2009; 37(12):2383-92. DOI: 10.1124/dmd.109.028860. View

16.

Matthews E, Ursem C, Kruhlak N, Benz R, Aragones Sabate D, Yang C . Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol. 2009; 54(1):23-42. DOI: 10.1016/j.yrtph.2009.01.009. View

17.

Will Y, Dykens J . Mitochondrial toxicity assessment in industry--a decade of technology development and insight. Expert Opin Drug Metab Toxicol. 2014; 10(8):1061-7. DOI: 10.1517/17425255.2014.939628. View

18.

Mesens N, Crawford A, Menke A, Hung P, Van Goethem F, Nuyts R . Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates?. J Appl Toxicol. 2015; 35(9):1017-29. DOI: 10.1002/jat.3091. View

19.

He J, Guo S, Zhu F, Zhu J, Chen Y, Huang C . A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. J Pharmacol Toxicol Methods. 2012; 67(1):25-32. DOI: 10.1016/j.vascn.2012.10.003. View

20.

Parng C . In vivo zebrafish assays for toxicity testing. Curr Opin Drug Discov Devel. 2005; 8(1):100-6. View